Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

24.2%

16 terminated/withdrawn out of 66 trials

Success Rate

75.4%

-11.1% vs industry average

Late-Stage Pipeline

58%

38 trials in Phase 3/4

Results Transparency

63%

31 of 49 completed trials have results

Key Signals

31 with results9 terminated7 withdrawn

Enrollment Performance

Analytics

Phase 3

29(46.8%)

Phase 2

13(21.0%)

Phase 4

9(14.5%)

Phase 1

7(11.3%)

N/A

4(6.5%)

62Total

Phase 3(29)

Phase 2(13)

Phase 4(9)

Phase 1(7)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (66)

Showing 20 of 66 trials

NCT02925416Phase 4Completed

Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection

Role: lead

NCT02452918Phase 4Completed

A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Role: lead

NCT02471690Phase 1Completed

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers

Role: lead

NCT00978822Phase 2Terminated

Safety and Efficacy Study of Clevidipine to Control Hypertension in Patients Admitted With Aneurysmal Subarachnoid Hemorrhage

Role: collaborator

NCT03021083Phase 4Withdrawn

IONSYS Feasibility Study

Role: collaborator

NCT01813435Phase 3Completed

GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

Role: collaborator

NCT02171065Not ApplicableCompleted

PROSPECT II & PROSPECT ABSORB - an Integrated Natural History Study and Randomized Trial.

Role: collaborator

NCT03397121Phase 3Completed

Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)

Role: lead

NCT00759083Phase 4Withdrawn

Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients

Role: lead

NCT04592380Phase 3Withdrawn

Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF

Role: lead

NCT03399370Phase 3Completed

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

Role: lead

NCT03400800Phase 3Completed

Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol

Role: lead

NCT02963311Phase 2Completed

A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

Role: lead

NCT01979445Phase 2Completed

Cangrelor to Clopidogrel or Prasugrel Transition Study

Role: lead

NCT01042574Phase 4Withdrawn

The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy

Role: collaborator

NCT02597127Phase 2Completed

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)

Role: lead

NCT00073580Phase 3Completed

Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)

Role: lead

NCT03159416Phase 1Completed

A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7)

Role: lead

NCT02565147Phase 3Terminated

Bivalirudin Infusion for Ventricular Infarction Limitation

Role: lead

NCT01033370Phase 4Terminated

A Safety and Efficacy Study of Blood Pressure Control in Acute Aortic Emergencies - A Pilot Study (PROMPT)

Role: collaborator